glucokinase activator
- Generic Name
- glucokinase activator
FDA Lifts Clinical Hold on vTv Therapeutics' Cadisegliatin for Type 1 Diabetes
• FDA has lifted the clinical hold on vTv Therapeutics' cadisegliatin program, allowing the CATT1 Phase 3 trial for type 1 diabetes to resume after addressing concerns about a chromatographic signal.
• The company plans to amend the protocol to shorten the trial duration from 12 to 6 months, expediting topline data collection while maintaining the original primary endpoint of measuring hypoglycemia rates.
• Cadisegliatin, a liver-selective glucokinase activator, has potential to become the first oral adjunctive therapy to insulin for type 1 diabetes, having been well-tolerated in over 500 subjects to date.
Conduit Pharmaceuticals Partners with Charles River to Advance Lupus Treatment Development
• Conduit Pharmaceuticals has partnered with Charles River Laboratories to evaluate its lead compound AZD1656 in a preclinical Systemic Lupus Erythematosus model, with results expected in Q2 2025.
• The collaboration aims to generate high-quality preclinical data to optimize development pathways and increase the probability of success for upcoming Phase II clinical trials in autoimmune disorders.
• Conduit is simultaneously advancing its intellectual property portfolio, securing composition-of-matter patents for AZD1656 Cocrystals in Japan and Australia, while developing novel solid oral-dosage formulations.
Conduit Pharmaceuticals Advances AI-Driven Drug Development Through Phase II Sarborg Collaboration
• Conduit Pharmaceuticals successfully completed Phase I of its strategic collaboration with Sarborg Limited, establishing foundations for AI integration in drug development processes.
• The collaboration focuses on leveraging artificial intelligence to enhance drug repurposing, accelerate discovery, optimize solid-form identification, and improve clinical trial monitoring.
• Phase II will implement personalized software dashboards for real-time clinical trial data monitoring and portfolio management, specifically targeting autoimmune disorder treatments.
Conduit Pharmaceuticals Secures Japanese Patent for AZD1656 Glucokinase Activator Targeting Autoimmune Disorders
• The Japan Patent Office has granted Conduit Pharmaceuticals a composition of matter patent for AZD1656, a Glucokinase Activator targeting autoimmune disorders including Lupus and ANCA Vasculitis.
• This approval follows a recent patent grant in Australia, strengthening Conduit's intellectual property portfolio in major pharmaceutical markets and enhancing future out-licensing opportunities.
• Conduit's business model focuses on enhancing existing pharmaceutical assets through solid-form technology, with the company holding exclusive licenses from AstraZeneca for multiple compounds including AZD1656.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath